Alan Main J.'s most recent trade in Lexicon Pharmaceuticals Inc was a trade of 68,243 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 68,243 | 136,487 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 68,243 | 382,538 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 43,434 | 339,104 (0%) | 0% | 0.7 | 29,101 | Common Stock |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 32,904 | 314,295 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 32,904 | 32,903 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 25,667 | 281,391 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 25,667 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 753,090 | 753,090 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 502,060 | 502,060 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,903 | 280,132 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,903 | 65,807 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | J. Main Alan | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 25,666 | 25,667 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | J. Alan Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 25,666 | 247,229 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 24,408 | 255,724 (0%) | 0% | 2.6 | 63,949 | Common Stock |
| Lexicon Pharmaceuticals Inc | Alan Main J. | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,977 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Main J. Alan | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,977 | 221,563 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Main J. Alan | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 204,730 | 204,730 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | J. Main Alan | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 204,730 | 204,730 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 25,667 | 233,532 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 25,667 | 51,333 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 23,300 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 23,300 | 198,889 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 20,946 | 212,586 (0%) | 0% | 2.2 | 45,453 | Common Stock |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,976 | 8,977 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,976 | 207,865 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 296,130 | 296,130 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 98,710 | 98,710 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 23,300 | 23,300 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 23,300 | 186,368 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 22,373 | 163,068 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 22,373 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 19,756 | 175,589 (0%) | 0% | 2.9 | 56,305 | Common Stock |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,977 | 17,953 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,977 | 195,345 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 230,990 | 230,990 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 77,000 | 77,000 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,300 | 46,600 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,300 | 161,108 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 22,374 | 137,808 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 22,374 | 22,373 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 20,413 | 140,695 (0%) | 0% | 7.2 | 146,769 | Common Stock |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,297 | 115,434 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,297 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,497 | 107,137 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,497 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 80,780 | 80,780 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 26,930 | 26,930 | - | - | Restricted Stock Units |